Immutep's diversified product portfolio harnesses LAG-3's ability to stimulate the immune response to fight cancer or modulate it to combat autoimmune diseases. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company is transitioning to Phase III operations with its lead candidate eftilagimod alfa progressing through pivotal trials.
Cyborg Score Rationale
Immutep has advanced its lead program (efti/IMP321) to Phase III with positive momentum and strong pharma partnerships. However, the company is pre-revenue from product sales and posted significant net losses despite growing service revenues, creating execution and cash runway risks typical of clinical-stage biotech.
Top Insights
Phase III transition underway: TACTI-004 trial in first-line NSCLC achieving 50% patient enrolment milestones with positive response rate data
Strong strategic partnerships with Merck, Novartis, and LabCorp de-risk development and provide validation of LAG-3 mechanism
Diversified pipeline across multiple oncology indications and autoimmune diseases positions company for multiple value catalysts
Revenue growth accelerating ($5.04M in 2025, +31% YoY) but substantial operating losses (-$61.43M) require careful capital management
Named Competitors
MSD LAG-3 Program — LAG-3 immunotherapy collaboration partner
Novartis LAG-3 Portfolio — LAG-3 research and development collaboration
PD-1/PD-L1 Checkpoint Programs — Established checkpoint inhibitor competition in similar cancer indications
Recent Developments
(February 2026) 50% patient enrolment achieved in Phase III TACTI-004 trial for first-line NSCLC
(May 2025) INSIGHT-003 trial showed high response rates for efti + Keytruda + chemotherapy in first-line NSCLC
(April 2025) TACTI-004 Phase III trial received first regulatory approval, marking company transition to Phase III biotech
Open the full interactive Immutep Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.